Aprea Therapeutics Inc (APRE) |
|
5.45 -0.32 (-5.55%)
|
03-05 09:20 |
|
Open: |
5.75 |
Pre. Close: |
5.77 |
|
High:
|
5.79 |
Low:
|
5.2 |
|
Volume:
|
955,384 |
Market Cap:
|
115M |
|
|
|
|
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The firm is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.799 - 5.839 |
5.839 - 5.87 |
|
Low:
|
5.102 - 5.153 |
5.153 - 5.192 |
|
Close:
|
5.377 - 5.448 |
5.448 - 5.503 |
|
Technical analysis |
as of: 2021-03-05 8:42:41 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 8.39 One year: 9.88 |
| Support: |
Support1: 5.12 Support2: 4.26 |
| Resistance: |
Resistance1: 7.18 Resistance2: 8.46 |
| Pivot: |
6.44 |
| Moving Average: |
MA(5): 5.84 MA(20): 6.59
MA(100): 16.10 MA(250): 24.87 |
| MACD: |
MACD(12,26): -0.67 Signal(9): -0.74  |
| Stochastic oscillator: |
%K(14,3): 7.72 %D(3): 10.24 |
| RSI: |
RSI(14): 31.52 |
| 52-week: |
High: 41.12 Low: 4.66 Change(%): -85.0 |
| Average Vol(K): |
3-Month: 178162 10-Days: 76237 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.APRE has closed above bottom band by 5.7%. Bollinger Bands are 77.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to APRE's normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 23 Feb 2021
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy - Nasdaq
Tue, 16 Feb 2021
What Kind Of Shareholders Own Aprea Therapeutics, Inc. (NASDAQ:APRE)? - Simply Wall St
Thu, 11 Feb 2021
Aprea Therapeutics Inc (APRE) Up 8.47% in Premarket Trading - InvestorsObserver
Wed, 10 Feb 2021
Aprea Therapeutics Inc (APRE) Stock: How Does it Score? - InvestorsObserver
Thu, 04 Feb 2021
Aprea Therapeutics Inc (APRE) Up 6.40% in Premarket Trading - InvestorsObserver
Wed, 03 Feb 2021
Is it Time to Dump Aprea Therapeutics Inc (APRE) Stock After it Is Higher By 29.55% in a Week? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
21 |
| Shares Float (M) |
10 |
|
% Held by Insiders
|
12.91 |
|
% Held by Institutions
|
87.80 |
|
Shares Short (K)
|
1,050 |
|
Shares Short P. Month (K)
|
1,070 |
Stock Financials |
|
EPS
|
-26.670 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
-59.910 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-39.5 |
|
Return on Equity (ttm)
|
-75.0 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.386 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-43 |
|
Levered Free Cash Flow (M)
|
-20 |
Stock Valuations |
|
PE Ratio
|
-0.20 |
|
PEG Ratio
|
|
|
Price to Book value
|
-0.09 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-2.66 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
